person · Reporting owner
Donley Matthew Maxwell
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Operating Officer | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 680,299 |
Ending reported balance
After 2026-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-27 · Grant · Acquired 58,160 · Balance 721,060 F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Row 2 · 2026-03-02 · Tax withholding · Disposed 40,761 · Balance 680,299 F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.97 · Expires 2036-02-27 | Direct | 97,256 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Grant · Acquired 97,256 · Balance 97,256 F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 36,975 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Grant · Disposed 36,975 · Balance 36,975 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2024-06-09 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2024-09-11 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-13 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2025-03-04 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-13 · Disposition to issuer · Disposed 28,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2026-03-02 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-13 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-02-13 · Disposition to issuer · Disposed 101,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 40,761 | $14.21 | $579,213.81 |
DisclosureSEC source: 0001600620-26-000022 · wk-form4_1772572450.xml · nonDerivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,299 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 97,256 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001600620-26-000022 · wk-form4_1772572450.xml · derivative · entry 3 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,256 Underlying: Common Stock · 97,256 shares Expires 2036-02-27 F3 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 58,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000022 · wk-form4_1772572450.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,060 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:08 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 32,901 | $14.40 | $473,774.40 |
DisclosureSEC source: 0001636642-26-000002 · wk-form4_1771880882.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,900 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 42,787 | $15.95 | $682,452.65 |
DisclosureSEC source: 0001600620-26-000004 · wk-form4_1767647524.xml · nonDerivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,801 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards. F3 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 30, 2025 and 1,457 common shares were acquired on November 28, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 54,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000004 · wk-form4_1767647524.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734,631 F1 · shares: Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 01:56 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 58,991 | $7.92 | $467,208.72 |
DisclosureSEC source: 0001600620-25-000018 · wk-form4_1741139793.xml · nonDerivative · entry 4 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,465 F6 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants. F7 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:56 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 65,902 | $8.00 | $527,216.00 |
DisclosureSEC source: 0001600620-25-000018 · wk-form4_1741139793.xml · nonDerivative · entry 3 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 739,456 F4 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:56 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 135,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000018 · wk-form4_1741139793.xml · nonDerivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,358 F3 · shares: Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:56 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 126,416 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001600620-25-000018 · wk-form4_1741139793.xml · derivative · entry 5 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,416 Underlying: Common Stock · 126,416 shares Expires 2035-02-28 F8 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:56 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 82,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000018 · wk-form4_1741139793.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,791 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. F2 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:43 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 40,665 | $5.51 | $224,064.15 |
DisclosureSEC source: 0001600620-24-000036 · wk-form4_1709847815.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Ops & Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 584,072 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 216,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000020 · wk-form4_1708637456.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Ops & Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624,737 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 271,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-006532 · wf-form4_167813816425740.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Ops & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,141 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 271,134 newly awarded RSUs, 104,080 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 27,927 shares of common stock. On March 2, 2023, 34,693 of Prior RSUs vested and 69,387 of Prior RSUs remained unvested. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:04 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 10,000 | $4.66 | $46,600.00 |
DisclosureSEC source: 0001628280-22-030745 · wf-form4_166923742713580.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Internal Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,927 F1 · balance_after: Includes 1,703 common stock of the Issuer acquired by the reporting person on May 31, 2022 pursuant to the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · derivative · entry 4 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · derivative · entry 3 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 3,052 | $12.01 | $36,654.52 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · nonDerivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,224 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,276 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 876 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:34 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 9,900 | $10.07 | $99,738.54 |
DisclosureSEC source: 0001628280-21-010023 · wf-form4_162085164781441.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 101,000 | $6.15 Strike: $11.85 | $621,150.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · derivative · entry 6 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $4.20 Strike: $13.80 | $315,000.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · derivative · entry 5 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 28,000 | $3.18 Strike: $14.82 | $89,040.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · derivative · entry 4 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2025-03-04 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | $11.25 Strike: $6.75 | $281,250.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · derivative · entry 3 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-09-11 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | $10.60 Strike: $7.40 | $1,590,000.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · derivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-06-09 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A | 36,975 | $18.00 | $665,550.00 |
DisclosureSEC source: 0001171843-18-001107 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,975 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). Read SEC document |
| December 31, 2017 Filed Jan 4, 2018 17:15 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 330 | $9.10 | $3,003.00 |
DisclosureSEC source: 0001171843-18-000177 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,975 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 16:58 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Tax withholdingCommon Stock, Class A | 19,353 | $17.98 | $347,966.94 |
DisclosureSEC source: 0001171843-18-000048 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,645 F1 · shares: The transaction reported represents the non-discretionary withholding of shares to satisfy the reporting person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. F2 · shares: Common stock originally granted consists of restricted stocked units; this award was originally scheduled to vest on March 2, 2020, but was accelerated to vest on December 28, 2017. Read SEC document |
| September 30, 2017 Filed Oct 5, 2017 16:37 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 330 | $9.10 | $3,003.00 |
DisclosureSEC source: 0001171843-17-005958 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,998 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document |
| June 30, 2017 Filed Jul 7, 2017 16:35 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 336 | $8.93 | $3,000.48 |
DisclosureSEC source: 0001171843-17-004000 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock. Read SEC document |
| March 31, 2017 Filed May 10, 2017 16:02 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 321 | $9.35 | $3,001.35 |
DisclosureSEC source: 0001171843-17-002918 · formfour.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Global HR, IT & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,332 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantEmployee Stock Option (right to buy) · Derivative | 101,000 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001171843-17-001361 · f4_donley030817.xml · derivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,000 Underlying: Class A Common Stock · 101,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: The option will vest over a four-year period, with 25% vesting on March 2, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon stock | 53,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-001361 · f4_donley030817.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 F1 · security: Common stock granted consists of restricted stock units that vest on March 2, 2020. Read SEC document |
| December 31, 2016 Filed Jan 6, 2017 16:02 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 286 | $10.46 | $2,991.56 |
DisclosureSEC source: 0001171843-17-000123 · f4_donley010617.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Exec.VicePres,HumanResources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock. Read SEC document |
| September 30, 2016 Filed Oct 21, 2016 16:05 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 320 | $9.38 | $3,001.60 |
DisclosureSEC source: 0001171843-16-012573 · f4_donley102116.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Exec.VicePres,HumanResources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.